GHRH and its engineered analogs can stimulate insulin secretion and protect pancreatic beta-cells, positioning them as potential new therapeutic peptides for type 2 diabetes and its complications.
Beta-cell preservationGHRH agonists not only stimulate insulin release but may protect the insulin-producing cells from dying — addressing a root cause of type 2 diabetes
What the researchers found
GHRH receptors are expressed on pancreatic beta-cells, and GHRH agonists can directly stimulate insulin secretion through signaling pathways similar to those used in the pituitary gland. Engineered GHRH analogs have been shown to:
- Increase insulin secretion from isolated pancreatic islets
- Preserve beta-cell function and survival
- Potentially improve glucose metabolism in type 2 diabetes
- Provide additional benefits including wound healing and cardioprotection
The review proposes that GHRH agonists could serve a dual role: improving insulin secretion while also protecting against diabetic complications like poor wound healing and cardiovascular damage.
Why it matters
Type 2 diabetes is fundamentally a disease of beta-cell failure — the insulin-producing cells gradually lose function over time. Most current diabetes drugs manage symptoms (blood sugar) rather than protecting the beta-cells themselves. If GHRH analogs can truly preserve beta-cell function and survival while also stimulating insulin secretion, they would address the root cause of the disease — a fundamentally different approach from existing treatments.
How the study worked
This is a review article that synthesizes research on GHRH receptor expression in peripheral tissues, particularly pancreatic islets. It examines preclinical studies on engineered GHRH agonists and antagonists, their signaling pathways in beta-cells, and their potential interactions with glucose-dependent insulin secretion mechanisms.
What this study cannot tell us
The evidence presented is primarily from preclinical studies — isolated pancreatic islets and animal models. No human clinical trials of GHRH analogs specifically for diabetes treatment are described. The long-term effects and safety of chronically stimulating GHRH receptors on beta-cells are unknown. There is also concern about potential off-target growth-promoting effects of GHRH agonists, which would need careful evaluation.
How to read the evidence
This is a review of primarily preclinical research, including in vitro studies on isolated pancreatic islets and early-stage investigations. While the mechanistic evidence is compelling, no human clinical trials are described. The evidence should be considered preliminary and hypothesis-generating.
When this study was published
Published in 2016, this review is somewhat dated. Research on GHRH analogs for diabetes has continued since then, though the field has been overshadowed by the dramatic clinical success of GLP-1-based therapies. The core findings about GHRH receptor expression on beta-cells remain valid.
The bigger picture
The discovery that GHRH receptors on pancreatic beta-cells can be therapeutically targeted adds to the growing list of peptide hormones being repurposed for diabetes treatment. While GLP-1 receptor agonists have already transformed diabetes care, GHRH analogs offer a complementary mechanism that focuses on beta-cell preservation and function. This is part of a broader trend toward peptide-based precision therapies that address specific cellular mechanisms of metabolic disease.
Questions still open
- Would GHRH agonists designed specifically for beta-cell targeting avoid unwanted growth hormone-related side effects?
- Could combining GHRH agonists with GLP-1 receptor agonists provide synergistic benefits for insulin secretion and beta-cell preservation?
- How do the cardioprotective and wound-healing effects of GHRH agonists compare to existing treatments for diabetic complications?
Common questions
How is GHRH different from growth hormone itself?
Could GHRH analogs replace current diabetes medications?
Read the original research
Growth Hormone-Releasing Hormone in Diabetes.
Frontiers in endocrinology, 7, 129
Citation
Fridlyand, Leonid E; Tamarina, Natalia A; Schally, Andrew V; Philipson, Louis H. (2016). Growth Hormone-Releasing Hormone in Diabetes.. Frontiers in endocrinology, 7, 129.